WO2001041812A3 - Amphiphilic polymers and polypeptide conjugates comprising same - Google Patents

Amphiphilic polymers and polypeptide conjugates comprising same Download PDF

Info

Publication number
WO2001041812A3
WO2001041812A3 PCT/US2000/033592 US0033592W WO0141812A3 WO 2001041812 A3 WO2001041812 A3 WO 2001041812A3 US 0033592 W US0033592 W US 0033592W WO 0141812 A3 WO0141812 A3 WO 0141812A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
amphiphilic polymers
peptides
proteins
polypeptide conjugates
Prior art date
Application number
PCT/US2000/033592
Other languages
French (fr)
Other versions
WO2001041812A2 (en
Inventor
Nnochiri N Ekwuribe
Original Assignee
Nobex Corp
Nnochiri N Ekwuribe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020027007500A priority Critical patent/KR20020068053A/en
Application filed by Nobex Corp, Nnochiri N Ekwuribe filed Critical Nobex Corp
Priority to MXPA02005885A priority patent/MXPA02005885A/en
Priority to BR0016339-2A priority patent/BR0016339A/en
Priority to IL15011900A priority patent/IL150119A0/en
Priority to HU0300133A priority patent/HUP0300133A2/en
Priority to AU20875/01A priority patent/AU2087501A/en
Priority to EP00984215A priority patent/EP1237580A2/en
Priority to JP2001543156A priority patent/JP2003516366A/en
Priority to CA002394928A priority patent/CA2394928A1/en
Publication of WO2001041812A2 publication Critical patent/WO2001041812A2/en
Publication of WO2001041812A3 publication Critical patent/WO2001041812A3/en
Priority to NO20022793A priority patent/NO20022793L/en
Priority to HK03101329.7A priority patent/HK1049283A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Proteins and/or peptides, such as luminal cholecystokinin releasing factor (LCRF), are conjugated with amphiphilic oligomers and polymers. Such conjugates may modulate the pharmacokinetic profile of the proteins and/or peptides, thereby improving their clinical utility. Such conjugates may also stabilize and deliver the proteins and/or peptides, such as LCRF, to receptors in the gut without absorption into the bloodstream.
PCT/US2000/033592 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same WO2001041812A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU20875/01A AU2087501A (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same
MXPA02005885A MXPA02005885A (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same.
BR0016339-2A BR0016339A (en) 1999-12-13 2000-12-11 Composition of lcrf, lcrf conjugate, peptide composition, lcrf complex conjugated to multiple ligand, polysorbate complex, conjugated lcrf complex, aqueous soluble stable, oral administration dosage form for the treatment of obesity, obesity treatment methods in a human or non-human mammalian patient, for prophylactic or interventional treatment of potential or developed obesity in a human or non-human mammalian patient and for prolongation of lcrf activity in an in vivo or in vitro system, and, composed
IL15011900A IL150119A0 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same
HU0300133A HUP0300133A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same
KR1020027007500A KR20020068053A (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same
EP00984215A EP1237580A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same
JP2001543156A JP2003516366A (en) 1999-12-13 2000-12-11 Amphiphilic polymer and polypeptide conjugate containing it
CA002394928A CA2394928A1 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same
NO20022793A NO20022793L (en) 1999-12-13 2002-06-12 Amphilic polymers as well as polypeptide conjugates containing them
HK03101329.7A HK1049283A1 (en) 1999-12-13 2003-02-21 Amphiphilic polymers and polypeptide conjugates comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/459,443 1999-12-13
US09/459,443 US6638906B1 (en) 1999-12-13 1999-12-13 Amphiphilic polymers and polypeptide conjugates comprising same

Publications (2)

Publication Number Publication Date
WO2001041812A2 WO2001041812A2 (en) 2001-06-14
WO2001041812A3 true WO2001041812A3 (en) 2002-03-21

Family

ID=23824795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033592 WO2001041812A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same

Country Status (18)

Country Link
US (2) US6638906B1 (en)
EP (1) EP1237580A2 (en)
JP (1) JP2003516366A (en)
KR (1) KR20020068053A (en)
CN (1) CN1434725A (en)
AU (1) AU2087501A (en)
BR (1) BR0016339A (en)
CA (1) CA2394928A1 (en)
CZ (1) CZ20021990A3 (en)
HK (1) HK1049283A1 (en)
HU (1) HUP0300133A2 (en)
IL (1) IL150119A0 (en)
MX (1) MXPA02005885A (en)
NO (1) NO20022793L (en)
PL (1) PL359174A1 (en)
RU (1) RU2002118709A (en)
WO (1) WO2001041812A2 (en)
ZA (1) ZA200204603B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
CA2473376A1 (en) 2002-01-16 2003-07-31 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CA2504287A1 (en) * 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
CN1761680A (en) 2002-12-26 2006-04-19 武田药品工业株式会社 Metastin derivative and use thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
JP2007509982A (en) * 2003-10-29 2007-04-19 アルタス ファーマシューティカルズ インコーポレイテッド Non-pancreatic protease for controlling plasma cholecystokinin (CCK) concentration and non-pancreatic protease for treating pain
PE20091567A1 (en) 2004-06-25 2009-11-03 Takeda Pharmaceutical METASTINE DERIVATIVES IN THE TREATMENT OF CANCER
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
WO2007011959A2 (en) * 2005-07-15 2007-01-25 Quintessence Biosciences, Inc. Methods and compositions for extracting membrane proteins
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (en) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co Metastin Derivatives And Use Thereof
EP2314609B1 (en) * 2008-07-30 2016-11-30 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
BR112013022052A2 (en) * 2011-03-01 2016-11-22 Novo Nordisk As dr3 antagonistic ligands
CN103740659B (en) * 2012-05-10 2015-06-03 江南大学 Enzymatic thermal stability improving method
CN103740661B (en) * 2012-05-10 2015-06-03 江南大学 Enzymatic thermal stability improving method
US20140039158A1 (en) * 2012-07-25 2014-02-06 Belrose Pharma, Inc. Polymeric conjugates and methods of preparing the same
CN106729735B (en) * 2017-03-09 2020-05-12 国家纳米科学中心 pH-sensitive polypeptide polymer and preparation method and application thereof
CA3097058A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
KR20240026573A (en) * 2022-08-22 2024-02-29 부산대학교 산학협력단 Polysorbate-Succinic anhydride-Carnitine Complex and Compositions for Delivering Physiologically Active Substances or Drugs Comprising the Same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1997015671A1 (en) * 1995-10-26 1997-05-01 Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ATE314843T1 (en) 1996-03-12 2006-02-15 Pg Txl Co Lp WATER SOLUBLE PACLITAXEL PRODRUGS
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ATE219363T1 (en) 1997-06-20 2002-07-15 Baker Norton Pharma SOLUBLE PRODRUGS OF PACLITAXEL
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (en) * 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1997015671A1 (en) * 1995-10-26 1997-05-01 Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor

Also Published As

Publication number Publication date
ZA200204603B (en) 2003-11-26
IL150119A0 (en) 2002-12-01
HK1049283A1 (en) 2003-05-09
NO20022793D0 (en) 2002-06-12
EP1237580A2 (en) 2002-09-11
NO20022793L (en) 2002-08-13
RU2002118709A (en) 2004-02-27
PL359174A1 (en) 2004-08-23
MXPA02005885A (en) 2002-10-23
HUP0300133A2 (en) 2003-05-28
KR20020068053A (en) 2002-08-24
CA2394928A1 (en) 2001-06-14
JP2003516366A (en) 2003-05-13
CN1434725A (en) 2003-08-06
AU2087501A (en) 2001-06-18
US20040092449A1 (en) 2004-05-13
WO2001041812A2 (en) 2001-06-14
CZ20021990A3 (en) 2002-11-13
US6638906B1 (en) 2003-10-28
BR0016339A (en) 2002-08-27

Similar Documents

Publication Publication Date Title
WO2001041812A3 (en) Amphiphilic polymers and polypeptide conjugates comprising same
CA2283939A1 (en) Non-antigenic branched polymer conjugates
CA2174325A1 (en) Non-antigenic branched polymer conjugates
AU2002224597A1 (en) Highly reactive branched polymer and proteins or peptides conjugated with the polymer
NO20015584D0 (en) Long-lasting insulin trophic peptides
EP1329458A3 (en) Peptides that lower blood glucose levels
AU6478400A (en) The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
DE69618028T2 (en) MEDICAL DELIVERY WITH COMPRESSION LUMEN
WO2001005434A3 (en) Hyaluronic acid-protein conjugates
CA2230492A1 (en) Human growth hormone variants
DE69937294D1 (en) DERIVED FROM CYCLOPHILIN B TUMORANTIGEN PEPTIDES
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
FR2791678B1 (en) 1,4-DIAZABICYCLO [3.2.2] NONANE-4-CARBOXYLATES AND -CARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EE03858B1 (en) Conjugates, their use in prostate cancer drugs, pharmaceutical composition and its preparation
WO2001011086A3 (en) Methods of screening for angiogenesis modulators
DE59709231D1 (en) IMPLANTS WITH PHASE DRUG DELIVERY
WO2002074344A3 (en) Peg-conjugates of hgt-nk4
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
DE69828394D1 (en) PHARMACEUTICAL COMPOSITION WITH LYOPHILIZED LYPOSOMES INCLUDING AN UNLIMITED ACTIVE ACTIVE SUBSTANCE, METHOD FOR THE PRODUCTION THEREOF
WO2002044197A3 (en) Cytokine receptor binding peptides
AU2575000A (en) Collagen-binding physiologically active polypeptide
WO2002097044A3 (en) Alternative splice forms of proteins as basis for multiple therapeutic modalities
EE9900218A (en) 1,4-Diazabicyclo [2.2.2] oct-2-ylmethyl benzoate derivatives, their preparation and their use in therapy
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
AU1761297A (en) Composite material for medical, cosmetic and sports purposes and methods for the preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2394928

Country of ref document: CA

Ref document number: PV2002-1990

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 150119

Country of ref document: IL

Ref document number: IN/PCT/2002/00752/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 519489

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027007500

Country of ref document: KR

Ref document number: 20875/01

Country of ref document: AU

Ref document number: PA/a/2002/005885

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 543156

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000984215

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002118709

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008189641

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027007500

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000984215

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1990

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 519489

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: PV2002-1990

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 519489

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000984215

Country of ref document: EP